Abbott Laboratories (ABT) shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value of 4.91X is significantly lower than the industry average of 7.64X and the benchmark’s average of 8.77.The stock also remains attractively valued compared to its peers like Boston Scientific (BSX) with a P/B of 6.47X and Stryker (SYK) with a P/B of 6.72.A low P/B compared to the industry average and competitors can present a buying opportunity for value investors on th ...

Michael (Mike) Dion is an FP&A, Corporate Finance, and Small Business expert who spent the last 12 years working in the Fortune 100, building a startup's finance and accounting department, advising small businesses, and guiding non-profit organizations as a board member. He has finance experience across multiple industries, including Telecom, Media and Entertainment, Hospitality, and Construction. He founded F9 Finance, a website that helps Finance professionals accelerate their careers; and simplifies Fina ...

Abbott (ABT) ended the recent trading session at $113.04, demonstrating a -0.69% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.55%. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq added 1.24%.Market participants will be closely following the financial results of Abbott in its upcoming release. The company plans to announce its earnings on January 22, 2025. The company is forecasted to report an EPS of $1.34, showcasing a 12.61% upwa ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Abbott (ABT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Abbott is a member of our Medical group, which includes 1011 different companies and currently sits at # ...

The MedTech industry has demonstrated resilience and growth throughout 2024 despite enduring persistent challenges such as supply chain disruptions, regulatory hurdles, and the need to adapt to rapidly advancing technologies. Notably, the Dow Jones U.S. Select Medical Equipment Index grew 10% during 2024, reflecting the sector's ability to adapt and innovate.Factors Likely to Drive Growth for the MedTech Space in 2025In 2025, the MedTech industry is likely to experience growth driven by technological advanc ...

Analyst's Position - The analyst holds beneficial long positions in shares of BTAFF, CVX, EOG, HSY, KO, PEP, PFE, PG, RBGPF, UNLYF, and XOM through stock ownership, options, or other derivatives [1] Article Context - The article reflects the personal opinions of the analyst and is not influenced by any compensation or business relationships with the mentioned companies [1] - The content is for informational purposes only and should not be considered as investment or tax advice [3] - The analyst is a private investor from Europe and shares their investing journey on Seeking Alpha [3]

A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets. In any case, it should have a solid track record of earnings growth and promising long-term prospects. It should be the sort of company that you can add to your portfolio, then sit back and relax -- because you're confident that this player will excel over time.It's the kind of stock you'll want to buy now and hold on to for the long haul, and by this, I mean ...

Abbott's (ABT) diversified business portfolio is well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently.Factors Driving ABT SharesAbbott’s Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users.In the third qu ...

Like all its peers, Abbott Laboratories (ABT) faced the industrywide challenges of margin pressure through 2024, stemming from growing inflation, labor shortages and supply chain disruptions, which increased operational costs. However, the company’s ability to pivot and deliver solid results in key areas underscores its resilience and strategic acumen. The company is poised to conclude 2024 on a strong and optimistic trajectory, focusing largely on strategic investments and operational efficiency.Abbott is ...

The latest trading session saw Abbott (ABT) ending at $114.31, denoting a +0.07% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.73%. Meanwhile, the Dow experienced a rise of 0.16%, and the technology-dominated Nasdaq saw an increase of 0.98%.Shares of the maker of infant formula, medical devices and drugs have depreciated by 3% over the course of the past month, outperforming the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 0.34%.Mar ...